PT2273994E - Formas de estado sólido de um produto farmacêutico - Google Patents

Formas de estado sólido de um produto farmacêutico Download PDF

Info

Publication number: PT2273994E
Authority: PT; Portugal
Prior art keywords: pharmaceutical; solid state; state forms; forms; solid
Prior art date: 2008-04-03

Application number

PT97267488T

Other languages

English (en)

Inventor

K White Steven

Ivanisevic Igor

Stephens Kyle

Andres Mark

Wolf Brenton

Original Assignee

Neurmedix Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-03

Filing date

2009-04-03

Publication date

2016-03-15

2009-04-03 Application filed by Neurmedix Inc filed Critical Neurmedix Inc

2016-03-15 Publication of PT2273994E publication Critical patent/PT2273994E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Transplantation (AREA)

PT97267488T 2008-04-03 2009-04-03 Formas de estado sólido de um produto farmacêutico PT2273994E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US4224008P	2008-04-03	2008-04-03

Publications (1)

Publication Number	Publication Date
PT2273994E true PT2273994E (pt)	2016-03-15

Family

ID=41136126

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT97267488T PT2273994E (pt)	2008-04-03	2009-04-03	Formas de estado sólido de um produto farmacêutico

Country Status (13)

Country	Link
US (9)	US8252947B2 (pt)
EP (1)	EP2273994B1 (pt)
JP (2)	JP2011527986A (pt)
KR (1)	KR101545300B1 (pt)
CN (1)	CN102215845A (pt)
AU (1)	AU2009231589B2 (pt)
CA (1)	CA2728889C (pt)
DK (1)	DK2273994T3 (pt)
ES (1)	ES2562069T3 (pt)
HU (1)	HUE028337T2 (pt)
PL (1)	PL2273994T3 (pt)
PT (1)	PT2273994E (pt)
WO (1)	WO2009124300A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102215845A (zh) *	2008-04-03	2011-10-12	哈博生物科学公司	药学试剂的固体形式
EP2300489B1 (en)	2008-06-06	2015-11-11	Harbor Therapeutics, Inc.	Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
US20120220560A1 (en) *	2010-12-17	2012-08-30	White Steven K	Steroid tetrol solid state forms
CN103768071B (zh) *	2012-10-23	2016-08-17	中国医药工业研究总院	一种治疗糖尿病的口服制剂
WO2019041078A1 (en) *	2017-08-28	2019-03-07	Zhejiang Jiachi Pharmaceutical Development Ltd.	ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
AU2022275684A1 (en) *	2021-05-18	2023-11-16	Biovie Inc.	Compositions for treatment of neurodegenerative conditions
WO2024054452A1 (en) *	2022-09-06	2024-03-14	Biovie Inc.	Methods for the treatment of mild cognitive impairment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4329366A (en) *	1979-11-08	1982-05-11	Johnson & Johnson Products, Inc.	Topical acylaminophenols
US4898694A (en) *	1987-11-25	1990-02-06	Schwartz Arthur G	17-Hydroxy-steroids
DE3801229A1 (de)	1988-01-18	1989-07-27	Krupp Polysius Ag	Mahlverfahren sowie mahlanlage
JP2642486B2 (ja)	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
EP0547151B1 (en) *	1990-08-29	2002-11-20	Humanetics Corporation	Treatment process for promoting weight loss employing a substituted delta 5-androstene
US5641766A (en) *	1990-08-29	1997-06-24	Humanetics Corporation	UP-regulation of immune system with Δ 5-Androstenes
US5292730A (en) *	1990-08-29	1994-03-08	Humanetics Corporation	Modulation of immune system with Δ5-androstenes
US5271944A (en)	1991-04-05	1993-12-21	Biofor, Ltd.	Pharmacologically enhanced formulations
US5922701A (en) *	1992-05-01	1999-07-13	University Of Utah Research Foundation	Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue
US5424077A (en)	1993-07-13	1995-06-13	Church & Dwight Co., Inc.	Co-micronized bicarbonate salt compositions
TW369521B (en)	1993-09-17	1999-09-11	Smithkline Beecham Corp	Androstenone derivative
US5455049A (en)	1995-01-04	1995-10-03	Ascent Pharmaceuticals, Inc.	Terfenadine oral powder
US5859000A (en) *	1995-06-07	1999-01-12	University Of Utah Research Foundation	Method for reducing mast cell mediated allergic reactions
US6686486B1 (en) *	1997-05-07	2004-02-03	Padma Marwah	Process for effecting allylic oxidation
US5869709A (en) *	1997-05-07	1999-02-09	Humanetics Corporation	Process for effecting allylic oxidation
ZA986614B (en) *	1997-07-25	1999-01-27	Gilead Sciences	Nucleotide analog composition
AU3088799A (en) *	1998-03-18	1999-10-11	Humanetics Corporation	Process for effecting allylic oxidation using dicarboxylic acid imides and chromium reagents
US20030083231A1 (en) *	1998-11-24	2003-05-01	Ahlem Clarence N.	Blood cell deficiency treatment method
US20080015174A1 (en) *	1998-11-24	2008-01-17	Reading Christopher L	Metabolic Disease Treatments
US20070129282A1 (en) *	1998-11-24	2007-06-07	Ahlem Clarence N	Pharmaceutical treatments and compositions
US6667299B1 (en) *	2000-03-16	2003-12-23	Hollis-Eden Pharmaceuticals, Inc.	Pharmaceutical compositions and treatment methods
US20060079492A1 (en) *	1999-10-25	2006-04-13	Ahlem Clarence N	Compositions and treatment methods
US20030060425A1 (en) *	1998-11-24	2003-03-27	Ahlem Clarence N.	Immune modulation method using steroid compounds
US7045513B1 (en) *	1999-03-18	2006-05-16	Genelabs Technologies, Inc.	DHEA composition and method
CA2670236C (en) *	1999-09-30	2012-06-05	Hollis-Eden Pharmaceuticals, Inc.	Therapeutic treatment of androgen receptor driven conditions
EP1223941B1 (en)	1999-10-25	2008-11-05	Hollis-Eden Pharmaceuticals Inc.	Therapeutic treatments for blood cell deficiencies using sreroids
US6274746B1 (en) *	2000-08-30	2001-08-14	Padma Marwah	Process for allylic oxidation using metal hypochlorite and alkyl hydroperoxide
EE05358B1 (et) *	2000-12-14	2010-12-15	Ortho-Mcneil Pharmaceutical, Inc.	Steroidhormoonprodukt ja selle valmistamismeetod
FR2820745A1 (fr) *	2001-02-14	2002-08-16	Oreal	Procedes de preparation de la 7alpha-hydroxy- dehydroepiandrosterone
AU2002352726A1 (en) *	2001-11-15	2003-06-10	Galileo Laboratories, Inc.	Formulations and methods for treatment or amelioration of inflammatory conditions
WO2004013622A1 (en)	2002-08-06	2004-02-12	Ssci, Inc.	Method of comparing x-ray diffraction patterns using the fundamental parameter method
EP1678484A2 (en)	2003-10-27	2006-07-12	SSCI, Inc.	Method for monte carlo indexing of powder diffraction data
US20070243620A1 (en)	2004-02-24	2007-10-18	Simon Bates	Analysis and Screening of Solid Forms Using the Atomic Pair Distribution Function
EP1807118B8 (en) *	2004-09-29	2014-04-23	Harbor Therapeutics, Inc.	Steroid analogs and characterization and treatment methods
US20060073099A1 (en) *	2004-10-01	2006-04-06	Frincke James M	Treatment screening methods
US20060211604A1 (en) *	2004-11-26	2006-09-21	The Brigham And Women's Hospital, Inc.	Methods for treating inflammatory disorders using regulators of microvessel dilations
US7964604B2 (en) *	2005-02-18	2011-06-21	Solvay Pharmaceuticals B.V.	Bifeprunox mesylate maintenance dose compositions and methods for using the same
KR20080112413A (ko)	2006-04-22	2008-12-24	홀리스-에덴 파마슈티칼즈, 인코포레이티드	약물 및 그 용도
US8217025B2 (en) *	2006-11-17	2012-07-10	Harbor Therapeutics, Inc.	Drug screening and treatment methods
US20080221074A1 (en) *	2006-11-17	2008-09-11	Jaime Flores-Riveros	Drug Screen and Treatment Method
US8354396B2 (en) *	2006-11-17	2013-01-15	Harbor Therapeutics, Inc.	Drug identification and treatment method
US20080153792A1 (en) *	2006-11-17	2008-06-26	Frincke James M	Drug Identification and Treatment Method
DE102007054497B3 (de) *	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
JP2011511011A (ja) *	2008-02-05	2011-04-07	ハーバーバイオサイエンシーズ，インコーポレイテッド	医薬的固体状態形態
CN102215845A (zh)	2008-04-03	2011-10-12	哈博生物科学公司	药学试剂的固体形式
EP2300489B1 (en) *	2008-06-06	2015-11-11	Harbor Therapeutics, Inc.	Methods for preparing 17-alkynyl-7-hydroxy steroids and related compounds
WO2010036822A1 (en) *	2008-09-24	2010-04-01	Hollis-Eden Pharmaceuticals, Inc.	Patient populations and treatment methods
US9310310B2 (en)	2011-08-26	2016-04-12	3M Innovative Properties Company	Flowable dry powder composition

2009
- 2009-04-03 CN CN2009801121621A patent/CN102215845A/zh active Pending
- 2009-04-03 PT PT97267488T patent/PT2273994E/pt unknown
- 2009-04-03 US US12/418,559 patent/US8252947B2/en active Active
- 2009-04-03 DK DK09726748.8T patent/DK2273994T3/en active
- 2009-04-03 AU AU2009231589A patent/AU2009231589B2/en active Active
- 2009-04-03 PL PL09726748T patent/PL2273994T3/pl unknown
- 2009-04-03 EP EP09726748.8A patent/EP2273994B1/en active Active
- 2009-04-03 WO PCT/US2009/039567 patent/WO2009124300A2/en active Application Filing
- 2009-04-03 JP JP2011503236A patent/JP2011527986A/ja not_active Withdrawn
- 2009-04-03 KR KR1020107024458A patent/KR101545300B1/ko active Active
- 2009-04-03 ES ES09726748.8T patent/ES2562069T3/es active Active
- 2009-04-03 HU HUE09726748A patent/HUE028337T2/en unknown
- 2009-04-03 CA CA2728889A patent/CA2728889C/en active Active
2012
- 2012-08-01 US US13/563,996 patent/US20120302537A1/en not_active Abandoned
- 2012-08-01 US US13/563,982 patent/US20120296105A1/en not_active Abandoned
2014
- 2014-08-14 US US14/459,528 patent/US9555046B2/en active Active
- 2014-08-14 US US14/459,493 patent/US9877972B2/en active Active
- 2014-12-01 JP JP2014242946A patent/JP2015042686A/ja active Pending
2016
- 2016-11-10 US US15/348,107 patent/US9850271B2/en active Active
2017
- 2017-12-21 US US15/851,523 patent/US20180208623A1/en not_active Abandoned
2019
- 2019-10-10 US US16/598,694 patent/US10995112B2/en active Active
2021
- 2021-04-26 US US17/240,728 patent/US20220002338A1/en active Pending

Also Published As

Publication number	Publication date
US9555046B2 (en)	2017-01-31
DK2273994T3 (en)	2016-02-01
KR101545300B1 (ko)	2015-08-18
KR20100132539A (ko)	2010-12-17
US8252947B2 (en)	2012-08-28
US20170152281A1 (en)	2017-06-01
CA2728889C (en)	2016-06-14
US20220002338A1 (en)	2022-01-06
US20160045516A1 (en)	2016-02-18
WO2009124300A2 (en)	2009-10-08
US20120296105A1 (en)	2012-11-22
EP2273994A2 (en)	2011-01-19
US9850271B2 (en)	2017-12-26
AU2009231589B2 (en)	2013-11-07
US20160175322A9 (en)	2016-06-23
US20160083415A1 (en)	2016-03-24
CA2728889A1 (en)	2009-10-08
CN102215845A (zh)	2011-10-12
US20180208623A1 (en)	2018-07-26
ES2562069T3 (es)	2016-03-02
EP2273994A4 (en)	2012-05-30
US10995112B2 (en)	2021-05-04
US20120302537A1 (en)	2012-11-29
JP2011527986A (ja)	2011-11-10
US9877972B2 (en)	2018-01-30
US20090291933A1 (en)	2009-11-26
WO2009124300A3 (en)	2011-06-23
EP2273994B1 (en)	2015-12-02
HUE028337T2 (en)	2016-12-28
US20200190133A1 (en)	2020-06-18
PL2273994T3 (pl)	2016-05-31
JP2015042686A (ja)	2015-03-05
AU2009231589A1 (en)	2009-10-08

Publication	Publication Date	Title
ZA201104336B (en)	2016-10-26	Pharmaceutical compounds
EP2339918A4 (en)	2012-06-06	PREPARATION OF A QUINOLINYLOXYDIPHENYLCYCLOPROPANEDICARBOXAMIDE
IL207378A0 (en)	2010-12-30	Pharmaceutical solid state forms
GB0816372D0 (en)	2008-10-15	Pharmaceutical compounds
GB0820819D0 (en)	2008-12-24	Pharmaceutical compounds
GB0801416D0 (en)	2008-03-05	Pharmaceutical compounds
IL216256A0 (en)	2012-01-31	A pharmaceutical composition
GB0816371D0 (en)	2008-10-15	Pharmaceutical compounds
SI2285413T1 (sl)	2012-09-28	Farmacevtski sestavek
GB0810615D0 (en)	2008-07-16	Novel pharmaceutical
ZA201104348B (en)	2012-02-29	Pharmaceutical preparation
GB0812969D0 (en)	2008-08-20	Pharmaceutical compounds
SI2271618T1 (sl)	2014-07-31	Farmacevtske spojine
GB0816370D0 (en)	2008-10-15	Pharmaceutical compounds
GB0815972D0 (en)	2008-10-08	Pharmaceutical preparation
GB0922589D0 (en)	2010-02-10	Pharmaceutical compounds
PL2273994T3 (pl)	2016-05-31	Postacie w stanie stałym leku
GB0810857D0 (en)	2008-07-23	Pharmaceutical compounds
ZA201008115B (en)	2012-01-25	A solid pharmaceutical formulation
IL245577A0 (en)	2016-06-30	Dose unit of efdanosone
GB0813347D0 (en)	2008-08-27	A set of parts
GB0810617D0 (en)	2008-07-16	Novel pharmaceutical
GB0908905D0 (en)	2009-07-01	Pharmaceutical compounds
GB0917775D0 (en)	2009-11-25	Novel pharmaceutical compounds
HU0800414D0 (en)	2008-08-28	Pharmaceutical combination